CD40 and neoplasm: CD40 agonism as monotherapy in advanced solid tumors had limited anti-tumor activity (196); however, use of a CD40 agonist in combination with PD-L1 and CTLA-4 blockade (see below) has shown extended survival in murine solid tumor models (197) (NCT02636725, NCT02332668).